Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q2 2024 Earnings Conference Call August 13, 2024 8:00 PM ET
Company Participants
Robert Barrow - CEO
Daniel Karlin - CMO
Reid Robison - Senior Principal Investigator, Cedar Clinical Research
Conference Call Participants
Elaine Kim - Cantor Fitzgerald
Brian Abrahams - RBC Capital Markets
Rudy Li - Leerink Partners LLC
Daniel Hultberg - Oppenheimer
Christopher Chen - Robert W. Baird
Sumant Kulkarni - Canaccord Genuity
Operator
Good morning, and welcome to the Mind Medicine Second Quarter 2024 Financial Results and Corporate Update Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on the investors and media section of MindMed's website at mindmed.co, and a recording will be available after the call.
I would now like to introduce Rob Barrow, CEO of MindMed. Please go ahead.
Robert Barrow
Thank you, and good morning, everyone. Welcome to our second quarter 2024 financial results and corporate update conference call.
Today, we will be sharing highlights from the second quarter along with the significant progress we've made with plans for our Phase 3 program in Generalized Anxiety Disorder, or GAD. Additionally, I'm excited to share further specifics about the expansion of our R&D program for MM120 into Major Depressive Disorder, or MDD, both of which are further supported by the financing we announced last week. The press release reporting our financial results and the presentation we will be using on today's call are both available in the investors and media section of our website, and our quarterly report on Form 10-Q for the quarter ended June 30, 2024 was filed this morning with the Securities and Exchange Commission.
During today's call and outlined on Slide 2, we will be making certain forward-looking statements, including, without limitation, statements about the potential safety, efficacy, and regulatory and clinical progress of our product candidates, our anticipated cash runway, and our future expectations, plans, partnerships and prospects. These statements are subject to various risks, such as changes in market conditions and difficulties associated with research and development and regulatory approval processes. These and other risk factors are described in the filings made with the SEC, including our annual report on Form 10-K and our Form 10-Q filed today.
Forward-looking statements are based on the assumptions, opinions and estimates of management of the date the statements are made, including the non-occurrence of the risks and uncertainties that are described in the filings made with the SEC, or other significant events occurring outside of MindMed's normal course of business. You are cautioned not to place undue reliance on these forward-looking statements, which are made as of today, August 13, 2024. MindMed disclaims any obligation to update such statements, even if management's views change except as required by law.